Dr. Rosenfeld is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3833 Greenbrier
Dallas, TX 75225Phone+1 214-810-8489
Education & Training
University of Nebraska Medical Center College of MedicineResidency, Internal Medicine, 1979 - 1982
University of Missouri Kansas City School of MedicineClass of 1979
University of Kansas School of MedicineFellowship, Hematology and Medical Oncology
Certifications & Licensure
TX State Medical License 1994 - 2020- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine
Clinical Trials
- Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Start of enrollment: 2005 May 01
- Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome Start of enrollment: 2007 Jan 01
Publications & Presentations
PubMed
- 306 citationsFluconazole prophylaxis of fungal infections in patients with acute leukemia: Results of a randomized placebo-controlled, double-blind, multicenter trialDrew J. Winston, Pranatharthi H. Chandrasekar, Hillard M. Lazarus, Jesse L. Goodman, Jeffrey L. Silber
Annals of Internal Medicine. 1993-04-01 - 643 citationsPhase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.Jean Pierre J. Issa, Guillermo Garcia-Manero, Francis J. Giles, Rajan Mannari, Deborah A. Thomas
Blood. 2004-03-01 - 29 citationsPilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome.Craig S. Rosenfeld, Cindi Bedell
Leukemia Research. 2002-08-01
Press Mentions
Collaborative Medicinal Development, LLC Reports That Lead Drug Shows Dose-Dependent Improvement in Parkinson's DiseaseJune 10th, 2019- Collaborative Medicinal Development LLC Wins AU$1 Million Grant Award from FightMNDApril 18th, 2019
Collaborative Medicinal Development, LLC Reports That Lead Drug Modifies ALS ProgressionJanuary 7th, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
